ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer patients after chemotherapy fails
Disease control CompletedThis study tested a chemotherapy drug called trifluridine/tipiracil in 52 women with advanced ER-positive, HER2-negative breast cancer that had already been treated with other chemotherapies. The goal was to see if the drug could slow cancer growth and improve quality of life. Th…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Borstkanker Onderzoek Groep • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise for advanced breast cancer in asian women
Disease control CompletedThis study tested whether adding palbociclib (a targeted cancer drug) to standard hormone therapy (letrozole) helps Asian postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The trial involved 340 women who had not received prior treatment for their ad…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo tested for advanced breast cancer in chinese women
Disease control CompletedThis early-stage study tested the drug palbociclib (combined with letrozole) in 26 postmenopausal Chinese women with a specific type of advanced breast cancer (ER+, HER2-). The main goal was to see how the drug moves through the body and to check for safety. The study is complete…
Matched conditions: ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC